|
US4331647A
(en)
|
1980-03-03 |
1982-05-25 |
Goldenberg Milton David |
Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5453566A
(en)
|
1986-03-28 |
1995-09-26 |
Calgene, Inc. |
Antisense regulation of gene expression in plant/cells
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
|
ATE115999T1
(de)
|
1987-12-15 |
1995-01-15 |
Gene Shears Pty Ltd |
Ribozyme.
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
GB8822492D0
(en)
|
1988-09-24 |
1988-10-26 |
Considine J |
Apparatus for removing tumours from hollow organs of body
|
|
US5211657A
(en)
|
1988-11-07 |
1993-05-18 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5549910A
(en)
|
1989-03-31 |
1996-08-27 |
The Regents Of The University Of California |
Preparation of liposome and lipid complex compositions
|
|
SG46445A1
(en)
|
1990-01-26 |
1998-02-20 |
Immunomedics Inc |
Vaccines against cancer and infectious diseases
|
|
JP3218637B2
(ja)
|
1990-07-26 |
2001-10-15 |
大正製薬株式会社 |
安定なリポソーム水懸濁液
|
|
US5789573A
(en)
|
1990-08-14 |
1998-08-04 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
|
|
JP2958076B2
(ja)
|
1990-08-27 |
1999-10-06 |
株式会社ビタミン研究所 |
遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
|
|
IL108367A0
(en)
|
1993-01-27 |
1994-04-12 |
Hektoen Inst For Medical Resea |
Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
|
|
SE9301916D0
(sv)
|
1993-06-03 |
1993-06-03 |
Ab Astra |
New peptides derivatives
|
|
SE9301911D0
(sv)
|
1993-06-03 |
1993-06-03 |
Ab Astra |
New peptide derivatives
|
|
US5801154A
(en)
|
1993-10-18 |
1998-09-01 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of multidrug resistance-associated protein
|
|
ZA951617B
(en)
|
1994-03-04 |
1997-02-27 |
Lilly Co Eli |
Antithrombotic agents.
|
|
US5741516A
(en)
|
1994-06-20 |
1998-04-21 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US5738868A
(en)
|
1995-07-18 |
1998-04-14 |
Lipogenics Ltd. |
Liposome compositions and kits therefor
|
|
US5739119A
(en)
|
1996-11-15 |
1998-04-14 |
Galli; Rachel L. |
Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
|
|
US5866573A
(en)
|
1997-04-21 |
1999-02-02 |
Merck & Co., Inc. |
Pyrazinone thrombin inhibitors
|
|
EP1082324A4
(en)
|
1998-05-26 |
2002-01-02 |
Merck & Co Inc |
IMIDAZOPYRIDINE COMPOUNDS AS THROMBINE INHIBITORS
|
|
KR20000047461A
(ko)
|
1998-12-29 |
2000-07-25 |
성재갑 |
트롬빈 억제제
|
|
AU3192500A
(en)
|
1999-03-16 |
2000-10-04 |
C & C Research Laboratories |
Substituted proline derivatives and medicinal compositions containing the same
|
|
US6664255B1
(en)
|
1999-05-19 |
2003-12-16 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
|
|
IL146245A0
(en)
|
1999-05-19 |
2002-07-25 |
Pharmacia Corp |
Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
|
|
US7015230B1
(en)
|
1999-05-19 |
2006-03-21 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
|
|
US6653316B1
(en)
|
1999-05-19 |
2003-11-25 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
|
|
US20040072862A1
(en)
|
1999-06-04 |
2004-04-15 |
Bitler Catherine M. |
Compositions for treating ischemia-related neuronal damage
|
|
US6649592B1
(en)
|
2000-01-14 |
2003-11-18 |
Science & Technology Corporation @ Unm |
Peptide inhibitors of LFA-1/ICAM-1 interaction
|
|
AU2001255399A1
(en)
|
2000-04-14 |
2001-10-30 |
Corvas International, Inc. |
Pyridine and pyrazine derivatives as thrombin inhibitors
|
|
AU2001222501A1
(en)
|
2000-05-18 |
2001-11-26 |
Pharmacia Corporation |
Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
|
|
SG98393A1
(en)
|
2000-05-19 |
2003-09-19 |
Inst Materials Research & Eng |
Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
|
|
CO5160330A1
(es)
|
2000-05-30 |
2002-05-30 |
Monsanto Co |
Reemplazo de arilo policiclico y heteroarilo pirimidinonas utiles para la inhibicion selectiva de una coagulacion en cascada
|
|
JP2004516286A
(ja)
|
2000-12-18 |
2004-06-03 |
メルク エンド カムパニー インコーポレーテッド |
ベンジルアミン誘導体およびそれのトロンビン阻害薬としての使用
|
|
WO2003028729A2
(en)
|
2001-10-03 |
2003-04-10 |
Pharmacia Corporation |
Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
|
|
EP1448534A1
(en)
|
2001-10-03 |
2004-08-25 |
Pharmacia Corporation |
6-membered unsaturated heterocyclic compounds useful for selective inhibition ofthe coagulation cascade
|
|
AU2003249317B2
(en)
|
2002-07-19 |
2007-08-02 |
Institute Of Materials Research And Engineering |
Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
|
|
WO2004032834A2
(en)
|
2002-10-04 |
2004-04-22 |
Merck & Co., Inc. |
Thrombin inhibitors
|
|
US7482376B2
(en)
|
2003-07-03 |
2009-01-27 |
3-Dimensional Pharmaceuticals, Inc. |
Conjugated complement cascade inhibitors
|
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US20140056873A1
(en)
|
2004-06-10 |
2014-02-27 |
University Of Leicester |
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
|
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
EP2386316B1
(en)
|
2004-06-10 |
2018-02-28 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
KR20080002832A
(ko)
|
2005-03-16 |
2008-01-04 |
얀센 파마슈티카 엔.브이. |
보체 매개성 질병 및 이상을 치료하기 위한 신규한 티오펜설폭시민
|
|
RU2008150485A
(ru)
|
2006-05-22 |
2010-06-27 |
Янссен Фармацевтика Н.В. (Be) |
Замещенные производные пиразинона для применения в качестве лекарственного средства
|
|
PL2104535T3
(pl)
|
2007-01-10 |
2011-05-31 |
Irm Llc |
Związki i kompozycje jako inhibitory proteazy aktywujące kanały
|
|
DE102009004113A1
(de)
|
2009-01-08 |
2010-07-15 |
Giesecke & Devrient Gmbh |
Verfahren zur Installation einer elektronischen Ticket- und/oder Bezahl-Applikation auf einem mobilen Endgerät
|
|
TW201100441A
(en)
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
|
CN102781471B
(zh)
|
2009-10-16 |
2016-10-12 |
奥默罗斯公司 |
通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
|
|
HUP1000366A2
(en)
|
2010-07-13 |
2012-03-28 |
Mta Enzimologiai Intezet |
Novel proteins, their production process and use tereof
|
|
EP2661433B1
(en)
|
2011-01-04 |
2017-08-16 |
Novartis AG |
Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
|
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
KR101870915B1
(ko)
|
2011-04-08 |
2018-06-25 |
유니버시티 오브 레스터 |
Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
|
|
EP2704743B1
(en)
|
2011-05-04 |
2020-03-11 |
Omeros Corporation |
Compositions for inhibiting masp-2 dependent complement acitivation
|
|
AU2013201779B2
(en)
|
2011-05-04 |
2016-01-07 |
Omeros Corporation |
Compositions for inhibiting MASP-2 dependent complement activation
|
|
ES2585244T3
(es)
|
2011-06-07 |
2016-10-04 |
Clevexel Pharma |
Composiciones y métodos para modular una cinasa
|
|
CA2861066C
(en)
|
2012-01-12 |
2024-01-02 |
Yale University |
Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
|
|
WO2013180834A2
(en)
|
2012-04-06 |
2013-12-05 |
Omeros Corporation |
Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria
|
|
KR102339315B1
(ko)
|
2012-06-18 |
2021-12-15 |
오메로스 코포레이션 |
다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
|
|
AR091490A1
(es)
*
|
2012-06-19 |
2015-02-11 |
Bristol Myers Squibb Co |
Antagonistas de iap
|
|
US20150273027A1
(en)
|
2012-10-10 |
2015-10-01 |
Novo Nordisk Healthcare Ag |
Liquid pharmaceutical composition of factor vii polypeptide
|
|
EP2922535B1
(en)
|
2012-11-20 |
2021-11-10 |
Merck Sharp & Dohme Corp. |
Thrombin inhibitors
|
|
SMT202000659T1
(it)
|
2013-10-17 |
2021-01-05 |
Omeros Corp |
Metodi per il trattamento delle condizioni associate all'attivazione del complemento dipendente dalla masp-2
|
|
BR112016015449A8
(pt)
|
2013-12-30 |
2020-06-09 |
Lifesci Pharmaceuticals Inc |
compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
|
|
HRP20200182T1
(hr)
|
2014-02-25 |
2020-05-01 |
Achillion Pharmaceuticals, Inc. |
Aril, heteroaril i heterociklični spojevi za liječenje komplementom posredovanih poremećaja
|
|
CN108472347B
(zh)
|
2015-11-09 |
2023-09-05 |
奥默罗斯公司 |
用于治疗与masp-2依赖性补体活化相关的病况的方法
|
|
US20170253667A1
(en)
|
2016-01-05 |
2017-09-07 |
University Of Leicester |
Methods for inhibiting fibrosis in a subject in need thereof
|
|
US10736960B2
(en)
|
2016-01-05 |
2020-08-11 |
Omeros Corporation |
Methods for inhibiting fibrosis in a subject in need thereof
|
|
WO2017173290A1
(en)
|
2016-03-31 |
2017-10-05 |
Omeros Corporation |
Methods for inhibiting angiogenesis in a subject in need thereof
|
|
JOP20170170B1
(ar)
|
2016-08-31 |
2022-09-15 |
Omeros Corp |
صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
|
|
US20180105604A1
(en)
|
2016-10-13 |
2018-04-19 |
University Of Leicester |
Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
|
|
TWI818919B
(zh)
|
2017-08-15 |
2023-10-21 |
美商歐米諾斯公司 |
用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
|
|
AU2018332887B2
(en)
|
2017-09-13 |
2022-12-08 |
Amgen Inc. |
Bisamide sarcomere activating compounds and uses thereof
|
|
GB201805174D0
(en)
*
|
2018-03-29 |
2018-05-16 |
Univ Leeds Innovations Ltd |
Compounds
|
|
GB201807014D0
(en)
|
2018-04-30 |
2018-06-13 |
Univ Leeds Innovations Ltd |
Factor xlla inhibitors
|
|
CN112867706B
(zh)
|
2018-05-29 |
2024-11-15 |
奥默罗斯公司 |
Masp-2抑制剂和使用方法
|
|
US11584714B2
(en)
|
2018-05-29 |
2023-02-21 |
Omeros Corporation |
MASP-2 inhibitors and methods of use
|
|
WO2021032933A1
(en)
|
2019-08-21 |
2021-02-25 |
Kalvista Pharmaceuticals Limited |
Enzyme inhibitors
|
|
EP4069676A1
(en)
|
2019-12-04 |
2022-10-12 |
Omeros Corporation |
Masp-2 inhibitors and methods of use
|
|
IL293550A
(en)
|
2019-12-04 |
2022-08-01 |
Omeros Corp |
2-masp inhibitor compounds, preparations containing them and their uses
|
|
JP7699389B2
(ja)
|
2019-12-04 |
2025-06-27 |
オメロス コーポレーション |
Ｍａｓｐ－２阻害剤および使用方法
|
|
BR112022010881A2
(pt)
|
2019-12-04 |
2022-08-23 |
Omeros Corp |
Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado a serina protease-2 associada à lectina de ligação ao manan
|